The Low Incidence of Secondary Acute Myelogenous Leukemia in Children and Adolescents Treated with Dexrazoxane for Acute Lymphoblastic Leukemia: A Report from the Dana-Farber Cancer Institute ALL Consortium

BACKGROUND: Dexrazoxane reduces the risk of anthracycline-related cardiotoxicity. In a study of children with Hodgkin lymphoma, the addition of dexrazoxane may have been associated with a higher risk for developing second malignant neoplasms (SMNs) including acute myelogenous leukemia (AML) and myel...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Vrooman, Lynda M., Neuberg, Donna S., Stevenson, Kristen E., Asselin, Barbara L., Athale, Uma H., Clavell, Luis, Cole, Peter D., Kelly, Kara M., Larsen, Eric C., Laverdière, Caroline, Michon, Bruno, Schorin, Marshall, Schwartz, Cindy L., Cohen, Harvey J., Lipshultz, Steven E., Silverman, Lewis B., Sallan, Stephen E.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3736806/
https://ncbi.nlm.nih.gov/pubmed/21514146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2011.03.022
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια